Cardax Inks Deal to Distribute ZanthoSyn® in China
HONOLULU, Feb. 17, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it has signed a Purchase Agreement (the "Agreement") with Health Elite Club Limited ("HECL") of Hong Kong for distribution of ZanthoSyn®, the Company's premium astaxanthin dietary supplement for inflammatory health and longevity, in China, Hong Kong, Macau, and Taiwan (the "Territories").
HECL is a Hong Kong based company founded by a group of entrepreneurs who are strong proponents of healthy aging. It is a membership-based, invitation-only club targeting high net worth / high-profile Chinese from the greater China area as the foundation for building large-scale consumer awareness. As is the custom in China, most sales will occur through an online platform.
ZanthoSyn® will be distributed in the Territories under HECL's house brand, Puerfons, with all packaging and marketing materials to feature the ZanthoSyn® brand. HECL is responsible for all regulatory approvals in the Territories and the Agreement is governed by the laws of New York.
"We are very pleased to be working with such a highly entrepreneurial company as HECL," said David G. Watumull, Cardax President and CEO. "HECL's distribution model looks quite promising and their principals are highly credible. We look forward to building our relationship as HECL's business grows in China."
"U.S. products with scientific and manufacturing credibility such as ZanthoSyn® are highly prized in China," said Li Wu, Chairman of HECL," and we are excited to bring Puerfons ZanthoSyn® into this important market. "With China's increasing industrialization and associated pollution challenges, inflammatory health, with its relationship to longevity, is increasingly important, especially to its rapidly growing aging population."
The agreement with HECL reflects Cardax's mission to develop and commercialize the safest, most effective anti-inflammatory products for health and longevity. Cardax is also developing and commercializing CDX-085, its next generation patented ZanthoSyn® product for more concentrated astaxanthin product applications. CDX-085 was chosen by the National Institutes of Health as a top anti-aging prospect.
"This expansion into China is another key building block of our goal to become the inflammatory health, anti-aging leader," added George W. Bickerstaff, Cardax Chairman.
Separately, Cardax announced that ZanthoSyn® is also available in GNC stores in Guam, where the Company will utilize the successful physician education and GNC outreach programs used in Hawaii to grow awareness in the local community and among Guam's many Asian visitors.
Cardax devotes substantially all of its efforts to developing and commercializing dietary supplements. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti-inflammatory that supports health and longevity.* The safety and efficacy of Cardax's products have not been directly evaluated in clinical trials or confirmed by the FDA.
About Health Elite Club
Health Elite Club is a Hong Kong based company founded by a group of entrepreneurs who are strong proponents of healthy aging. The mission of HECL is to bring cutting edge products and services to its valued clients. HECL also promotes healthy lifestyles and creates customized solutions based on individual health conditions. HECL is a membership-based, invitation-only club targeting high net worth / high-profile Chinese from the greater China area.
ZanthoSyn® is a physician recommended anti-inflammatory supplement for health and longevity that features astaxanthin with optimal absorption and purity.* ZanthoSyn® is sold online and in GNC stores. ZanthoSyn® contains astaxanthin, which is Generally Recognized as Safe (GRAS) according to FDA regulations.
Astaxanthin is a clinically studied compound with safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, liver health, and longevity.*
Media and Investors
This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
View original content with multimedia:http://www.prnewswire.com/news-releases/cardax-inks-deal-to-distribute-zanthosyn-in-china-300600428.html
SOURCE Cardax, Inc.
Released February 17, 2018